IGN

Le Touquet – Paris-Plage, France
Le Touquet – Paris-Plage, France
SEARCH FILTERS
Time filter
Source Type

News Article | April 25, 2017
Site: globenewswire.com

Entre les exigences de plus en plus fortes des consommateurs (attrait de la nouveauté, équité, traçabilité, sécurité.), les nouvelles contraintes réglementaires et environnementales et la hausse du coût des matières premières (graines, engrais, pesticides, eau.), le secteur agricole est sous pression. Atos s'appuie sur la dernière génération de satellites d'observation terrestre Sentinel-2, conçue par l'Agence spatiale européenne (ASE) et capable de fournir des panoramas à l'aide de lumière visible et proche infrarouge avec une résolution de 10 à 60 m, dans un périmètre de 290 km et avec une fréquence de répétitivité de cinq jours, idéale pour surveiller les récoltes. Atos analyse pour un de ses grands clients aux Etats-Unis plus de 100 000 hectares de récoltes et 6 000 parcelles de terre (recouvertes de blé, maïs, soja et légume) pour fournir des indicateurs biophysiques sur le développement des plantes comme la chlorophylle ou la proportion de feuillage vert. Cette surveillance permet de détecter des anomalies ou des différences dans et entre les parcelles de terre. En connectant ces informations aux données du terrain et grâce à la suite de solutions de business analytics Atos Codex, les experts peuvent ensuite fournir des diagnostics et suggérer des ajustements des pratiques agricoles. Philippe Miltin, Vice-président du groupe Atos, directeur du secteur Fabrication et Distribution, explique : « Grâce à la puissance et à la flexibilité des nouveaux outils cognitifs et analytiques, nous pouvons exploiter pleinement les données. Elles permettent à nos clients d'améliorer leurs pratiques et de s'adapter à leurs nouveaux besoins environnementaux, sociaux, réglementaires et économiques. En coopération avec la start-up TerraNIS, nous relevons ces défis multiples en combinant compétences avancées en imagerie et agronomie avec les fonctionnalités d'Atos Codex. » Retrouvez les cas d'usage (en anglais) : Thanks to Atos and TerraNIS La Coop Fédérée is turning to precision in agriculture Data Analytics - Transforming the future of agriculture *Le consortium, baptisé SparkInData, a plusieurs membres : Atos en tant que leader du consortium, les PME TerraNIS, Geomatys et Geosigweb, Mercator-Ocean, le CNES (Centre National d'Études Spatiales), l'IGN (Institut National de l'Information Géographique et Forestier), le BRGM (Bureau des Recherches Géologiques et Minières), l'IRIT (Institut de Recherche Informatique de Toulouse à l'Université Paul-Sabatier), l'École d'ingénieurs de Purpan et le pôle de compétitivité Aerospace Valley. À propos d'Atos Codex Atos Codex est la marque d'Atos pour les Analytics, l'Internet des Objets et les solutions cognitives. Atos  Codex comprend une méthodologie, des Design Labs, une plateforme industrielle  ouverte  ainsi que des Data Analytics de haute performance fournissant une gamme complète de produits et de services pour concevoir et exécuter des plateformes commerciales digitales. Atos Codex est l'un des quatre piliers de la Digital Transformation Factory d'Atos - aux côtés d'Atos Canopy, le Cloud  Hybride Orchestré d'Atos ; SAP HANA par Atos et l'Atos Digital Workplace - permettant d'accompagner la transformation digitale des clients. À propos d'Atos Atos is a global leader in digital transformation with approximately 100,000 employees in 72 countries and annual revenue of around € 12 billion. The European number one in Big Data, Cybersecurity, High Performance Computing and Digital Workplace, The Group provides Cloud services, Infrastructure & Data Management, Business & Platform solutions, as well as transactional services through Worldline, the European leader in the payment industry. With its cutting-edge technologies, digital expertise and industry knowledge, Atos supports the digital transformation of its clients across various business sectors: Defense, Financial Services, Health, Manufacturing, Media, Energy & Utilities, Public sector, Retail, Telecommunications and Transportation. The Group is the Worldwide Information Technology Partner for the Olympic & Paralympic Games and operates under the brands Atos, Atos Consulting, Atos Worldgrid, Bull, Canopy, Unify and Worldline. Atos SE (Societas Europaea) is listed on the CAC40 Paris stock index.


News Article | April 19, 2017
Site: news.yahoo.com

"Super Mario World" has appeared on the SNES, 3DS, Wii and Wii U. Could the SNES Classic be next in line? In 2016, it was the NES Mini Classic. For 2017, Nintendo just might be preparing an all-in-one version of its early 90s home console, the SNES, according to a new report. As the Nintendo Entertainment System's tiny official remake, the Nintendo Classic Edition (or Nintendo Classic Mini,) is being prepared for retirement, an eagerly awaited successor is said to be waiting in the wings. Nintendo is winding down distribution for the NES Classic, having explained that the machine "wasn't intended to be an ongoing, long-term product" in an April 13 statement to IGN. Now it seems that manufacturing capacity is being retained, with an SNES Classic Edition in mind for the end of 2017. Should territorial distinctions continue, it could be called a Nintendo Classic Mini: Super Nintendo Entertainment System in Europe, or a Nintendo Classic Mini: Super Famicom in Japan, according to the console's original naming conventions. That a small, throwback SNES would be in the works has been suggested by fans and observers since the NES Classic proved such a hit in 2016. It's not just wishful thinking, according to Eurogamer, which cites "sources close to the company" in its report. The NES Classic contained 30 emulated games, meaning that owners did not need to supply original game cartridges. Neither could they add extra NES games to the console, as it could not link up with Nintendo's Virtual Console service present on more modern hardware, unless they overwrote the Classic's software with a different operating system and imported another suite of emulated games, which some chose to do. Vintage titles such as "Donkey Kong," "Metroid," "Mega Man 2," "Super Mario Bros" and its two direct sequels and the first the "Legend of Zelda" games were part of the package. Best-sellers from the SNES era, and therefore potential candidates for a SNES Classic, include "Super Mario World," "Donkey Kong Country," "Super Mario Kart," "The Legend of Zelda: A Link to the Past," "Super Mario World 2: Yoshi's Island," "F-Zero" and "Pilotwings."


LAUSANNE, Switzerland & WALTHAM, Mass.--(BUSINESS WIRE)--Debiopharm International SA (Debiopharm – www.debiopharm.com), part of Debiopharm Group™, a Switzerland-based biopharmaceutical company, and ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Debiopharm has acquired ImmunoGen’s IMGN529/DEBIO 1562, a clinical-stage anti-CD37 ADC for the treatment of patients with B-cell malignancies, such as non-Hodgkin lymphomas (NHL). Under the terms of the agreement, ImmunoGen received a $25 million upfront payment for IMGN529/DEBIO 1562 and is entitled to a $5 million milestone payment to be paid after completion of the transfer of ImmunoGen technologies related to the asset, which the parties expect to achieve by the end of 2017. In addition, ImmunoGen is eligible for a second success-based milestone payment of $25 million upon IMGN529/DEBIO 1562 entering a Phase 3 clinical trial. “The purchase of IMGN529/DEBIO 1562 from a pioneer in the field of ADCs represents a strategic investment leveraging our expertise and track record in Oncology and supports our strong commitment to deliver targeted therapies and precision medicines to help patients suffering from severe diseases,” stated Bertrand Ducrey, CEO of Debiopharm. “IMGN529/DEBIO 1562 has already generated compelling clinical data and we look forward to further exploring it in combination with Rituxan®, which could provide an attractive alternative to conventional chemotherapies for patients with NHL such as diffuse large-cell B-cell lymphoma (DLBCL),” said Chris Freitag, vice president of clinical research and development of Debiopharm. IMGN529/DEBIO 1562 demonstrated evidence of anticancer activity in NHL in a Phase 1 monotherapy trial and successfully completed a safety run-in study in combination with Rituxan®. The product is now ready to move forward into a Phase 2 trial in NHL, and particularly in DLBCL for which it has Orphan Drug status. “With a strong history of developing and bringing oncology drugs to market, Debiopharm offers the right mix of resources and capabilities to advance IMGN529/DEBIO 1562 through its next phase of development,” stated Mark Enyedy, president and chief executive officer of ImmunoGen. “Consistent with the strategic review of our portfolio undertaken last fall, this transaction further enables us to prioritize our development efforts on mirvetuximab soravtansine and our IGN programs, while generating near-term value from IMGN529/DEBIO 1562.” About Debiopharm International SA Part of Debiopharm Group™ – a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management – Debiopharm International SA focuses on developing prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide. For more information, please see www.debiopharm.com We are on Twitter. Follow @DebiopharmNews at http://twitter.com/DebiopharmNews About ImmunoGen, Inc. ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com. Kadcyla® and Rituxan® are the registered trademarks of their respective owners. This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including IMGN529/DEBIO 1562, including risks relating related to clinical studies, their timing and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the six-month period ended December 31, 2016 and other reports filed with the Securities and Exchange Commission.


News Article | May 24, 2017
Site: www.businesswire.com

PARIS--(BUSINESS WIRE)--Zombie Gunship Survival, the new installment in the #1 top-grossing Zombie Gunship franchise has released globally on App Store for iPhone and iPad and on Google Play for Android devices. Zombie Gunship Survival is a mobile shooter – free to download – with a user interface that will be familiar to FPS fans. Delivering a gritty, intense simulation in place of the arcade-shooter gameplay commonly found on mobile, the game puts players in direct control of the scenario-based action from the gunner seat of an AC-130 aircraft. The story continues on from the IGN Editors’ Choice Award winning Zombie Gunship, with players taking to the skies to wage war against the undead several months after the outbreak of a devastating zombie apocalypse. By protecting ground troops during risky scavenging missions and securing valuable resources, players must safeguard the future of humanity by building a remote airfield, which acts both as a shelter for survivors and a base for operations. But with unrelenting zombie attacks, players will need to unlock and upgrade over 30 different weapons – from autocannons and rocket pods to rifles and submachine guns – to keep the hordes at bay. Published by flaregames (Nonstop Chuck Norris, Nonstop Knight, Royal Revolt 2) and developed by Limbic (TowerMadness, Nuts!), Zombie Gunship Survival has been created by a top team of industry veterans including Jeff Miller (formerly Ubisoft, LucasArts) as Art Director, Eric Froemling (formerly Pixar) as Visual Effects Engineer, Constantine Hantzopoulos (formerly Looking Glass, Sega, Hasbro) and Borja Guillan (formerly PopCap Games) as Game Lead at flaregames. “Redefining how gamers perceive shooters on mobile while successfully evolving a franchise that is loved by millions is no easy feat,” said Klaas Kersting, flaregames CEO and founder. “With such an enormous amount of work invested during development, the final game is a true testament to the world-class skills of the team and the incredible 3D engine powering the experience.” “The Zombie Gunship franchise was designed to give the most demanding of audiences an interactive, realistic and immersive kind of gameplay that is rare on mobile,” said Arash Keshmirian, Limbic’s CEO and Creative Director. “The raw, awesome power of the AC-130 gunship, and our commitment to high production value drives an uncommonly visceral experience in Survival. We believe we’ve built an experience that millions of fans and new players alike will enjoy.” For more information, please visit: http://zombiegunship.com/en/ flaregames is a fast-growing mobile game publisher and developer based in Germany, with its HQ in Karlsruhe and its development studios in Frankfurt (Keen Flare) and Tampere (Kopla Games). The company was founded in 2011 by Klaas Kersting, former CEO and founder of online games category leader Gameforge, and has raised $23 million in venture backing from investors such as Accel Partners and Deutsche Telekom Strategic Investments. Committed to working with world-class mobile game developers to create fun, high-quality, free-to-play games for smartphones and tablets, flaregames is best known for Nonstop Chuck Norris, Nonstop Knight and the Royal Revolt series. Limbic is an independent entertainment company founded in 2008, and the creator of mobile games TowerMadness, Nuts!, and Zombie Gunship. The studio's award-winning debut title, TowerMadness, launched in 2009 innovating with a proprietary 3D engine and global cloud leaderboards. With craftsmanship and a commitment to improving the player’s overall gaming experience, Limbic has won over a legion of dedicated fans across the world. In Summer 2011, Limbic launched two franchises, Nuts! and Zombie Gunship, both of which achieved Top-3 status on the App Store. Limbic's hit sequel TowerMadness 2 in 2014 was featured in the New York Times, and selected as App of the Week on the App Store. For the past two years, Limbic has been hard at work on its most ambitious project yet, Zombie Gunship Survival.


News Article | May 29, 2017
Site: www.businesswire.com

LOS ANGELES--(BUSINESS WIRE)--j2 Global, Inc. (NASDAQ:JCOM) today announced its participation at two investor conferences in June 2017. Details of the conferences are as follows: Baird Global Consumer, Technology & Services Conference Location: InterContinental New York Barclay Hotel, New York, New York Presenter: Scott Turicchi, President and Chief Financial Officer of j2 Global Presentation Time: Wednesday, June 7, 2017, at 9:05 AM (ET) Webcast: http://wsw.com/webcast/baird48/jcom William Blair 37th Annual Growth Stock Conference Location: Four Seasons Hotel, Chicago, Illinois Presenter: Scott Turicchi, President and Chief Financial Officer of j2 Global Presentation Time: Wednesday, June 14, 2017, at 2:00 PM (CT) Webcast: http://wsw.com/webcast/blair53/jcom j2 Global, Inc. (NASDAQ: JCOM) provides Internet services through two segments: Business Cloud Services and Digital Media. The Business Cloud Services segment offers Internet fax, virtual phone, unified communications, hosted email, email marketing, online backup and CRM solutions. It markets its services principally under the brand names eFax ®, eVoice ®, Onebox ®, FuseMail ®, Campaigner ®, KeepItSafe ®, Livedrive® and LiveVault®, and operates a messaging network spanning 50 countries on six continents. The Digital Media segment offers technology, gaming, lifestyle and healthcare content through its digital properties, which include PCMag, IGN, AskMen, Speedtest, Offers, ExtremeTech, Geek, Toolbox, Techbargains, emedia, Salesify, Everyday Health and others. As of December 31, 2016, j2 had achieved 21 consecutive fiscal years of revenue growth. For more information about j2, please visit www.j2global.com.


Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group™, a Switzerland-based biopharmaceutical company, and ImmunoGen, Inc (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Debiopharm has acquired ImmunoGen's IMGN529/Debio 1562, a clinical-stage anti-CD37 ADC for the treatment of patients with B-cell malignancies, such as non-Hodgkin lymphomas (NHL). Under the terms of the agreement, ImmunoGen received a $25 million upfront payment for IMGN529/Debio 1562 and is entitled to a $5 million milestone payment to be paid after completion of the transfer of ImmunoGen technologies related to the asset, which the parties expect to achieve by the end of 2017. In addition, ImmunoGen is eligible for a second success-based milestone payment of $25 million upon IMGN529/Debio 1562 entering a Phase 3 clinical trial. "The purchase of IMGN529/Debio 1562 from a pioneer in the field of ADCs represents a strategic investment leveraging our expertise and track record in Oncology and supports our strong commitment to deliver targeted therapies and precision medicines to help patients suffering from severe diseases" stated Bertrand Ducrey, CEO of Debiopharm. "IMGN529/Debio 1562 has already generated compelling clinical data and we look forward to further exploring it in combination with Rituxan®, which could provide an attractive alternative to conventional chemotherapies for patients with NHL such as diffuse large-cell B-cell lymphoma (DLBCL)," said Chris Freitag, Vice President of Clinical Research & Development of Debiopharm. IMGN529/Debio 1562 demonstrated evidence of anticancer activity in NHL in a Phase 1 monotherapy trial and successfully completed a safety run-in study in combination with Rituxan®. The product is now ready to move forward into a Phase 2 trial in NHL, and particularly in DLBCL for which it has Orphan Drug status. "With a strong history of developing and bringing oncology drugs to market, Debiopharm offers the right mix of resources and capabilities to advance IMGN529/Debio 1562 through its next phase of development," stated Mark Enyedy, President and Chief Executive Officer of ImmunoGen. "Consistent with the strategic review of our portfolio undertaken last fall, this transaction further enables us to prioritize our development efforts on mirvetuximab soravtansine and our IGN programs, while generating near-term value from IMGN529/Debio 1562." Part of Debiopharm Group™ -  a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management - Debiopharm International SA focuses on developing prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide. For more information, please see http://www.debiopharm.com We are on Twitter. Follow @DebiopharmNews at http://twitter.com/DebiopharmNews ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at http://www.immunogen.com. Kadcyla® and Rituxan® are the registered trademarks of their respective owners. This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including IMGN529/Debio 1562, including risks relating related to clinical studies, their timing and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the six-month period ended December 31, 2016 and other reports filed with the Securities and Exchange Commission.


News Article | May 23, 2017
Site: www.marketwired.com

Upcoming Events: IGEN's Nimbo Tracking to Sponsor AE Agent Summit and CEO to Present at LD Micro Invitational MURRIETA, CA--(Marketwired - May 23, 2017) - IGEN Networks Corporation ( : IGEN) ( : IGN), a Company that offers a range of cloud-based wireless IoT solutions with a focus on asset management and tracking for the automotive dealership industry, announces that it filed its first quarter 2017 financials. In addition, IGEN's Nimbo Tracking will attend & sponsor the AE Agent Summit May 21-24 at the Paris Hotel in Las Vegas, and CEO Neil Chan will present at the 7th Annual LD Micro Invitational that takes place in Los Angeles, CA June 6-7. Notable achievements for the quarterly period ended March 31, 2017 include the following: CEO Neil Chan stated, "We continue to see growth in revenues and are particularly pleased with the significant improvement in gross margins." Mr. Chan added, "We are on track to achieve our 2017 goals of converting dealership groups to our pre-load model and to achieve profitability by year end 2017." IGEN subsidiary Nimbo Tracking will attend and sponsor the AE Agent Summit 2017. Designed exclusively for automotive general agents, the goal of this event is to educate top GAs on the latest training techniques, trends and challenges to help them better serve their dealer clients. The 7th Annual LD Micro Invitational will highlight some of the best names in the micro-cap space. IGEN Networks will present and attend the conference. More information can be found at www.LDMicro.com. IGEN Networks Corporation is a service provider that delivers cloud-based services for the protection, management, and improved productivity of consumer and commercial assets. IGEN is a fully reporting company in both Canada and the United States. It is publicly traded on the OTCQB under the symbol IGEN, and listed on the CSE under the symbol IGN. For more information, please visit www.igen-networks.com and www.NimboTracking.com. This news release may contain forward-looking statements or forward looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities law. The terms and phrases "goal", "commitment", "guidance", "expects", "would", "will", "continuing", "drive", "believes", "indicate", "look forward", "grow", "outlook", "forecasts", "intend", and similar terms and phrases are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by IGEN in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that IGEN believes are appropriate in the circumstances, including but not limited to statements regarding investment liquidity, financing options and long term goals of the Company, general economic conditions, IGEN's expectations regarding its business, customer base, strategy and prospects, and IGEN's confidence in the cash flow generation of its business. Many factors could cause IGEN's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation: risks related to competition; IGEN's reliance on key personnel; IGEN's ability to maintain and enhance its brand; and difficulties in forecasting IGEN's financial results, particularly over longer periods given the rapid technological changes, competition and short product life cycles that characterize the mobile application industry. These risk factors and others relating to IGEN that may cause actual results to differ are set forth in the under the heading "Risk Factors" in IGEN's periodic filings with the British Columbia Securities Commission and the U.S. Securities and Exchange Commission (copies of which filings may be obtained at www.sedar.com or www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on IGEN's forward-looking statements. IGEN has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


News Article | May 8, 2017
Site: www.businesswire.com

LOS ANGELES--(BUSINESS WIRE)--j2 Global, Inc. (NASDAQ: JCOM) today reported financial results for the first quarter ended March 31, 2017 and announced that its Board of Directors has declared an increased quarterly cash dividend of $0.3750 per share. Q1 2017 quarterly revenues increased 27.0% to an all time record of $254.7 million compared to $200.5 million for Q1 2016. Net cash provided by operating activities decreased by 20.6% to $51.2 million compared to $64.5 million for Q1 2016. This decrease was driven by a $20.0 million payment of certain contingent compensation obligations of Everyday Health as well as payments of $22.0 million for general and acquisition related accrued expenses, specific to Everyday Health paid out in Q1 2017. Q1 2017 free cash flow(1) increased by 1.7% to $61.5 million compared to $60.5 million for Q1 2016 before the effects of payments associated with certain contingent compensation associated with the acquisition of Everyday Health. GAAP earnings per diluted share(2) decreased 14.8% to $0.52 in Q1 2017 compared to $0.61 for Q1 2016. Adjusted non-GAAP earnings per diluted share(2)(3) for the quarter increased 13.3% to $1.19 compared to $1.05 for Q1 2016. GAAP net income decreased by 13.7% to $25.8 million compared to $29.9 million for Q1 2016. Quarterly Adjusted EBITDA(4) increased 14.8% to $99.5 million compared to $86.7 million for Q1 2016. j2 ended the quarter with approximately $187.5 million in cash and investments after deploying approximately $23.5 million during the quarter for acquisitions and j2’s regular quarterly dividend. Key financial results for Q1 2017 versus Q1 2016 are set forth in the following table (in millions, except per share amounts). Reconciliations of Adjusted non-GAAP earnings per diluted share, Adjusted EBITDA and free cash flow to their nearest comparable GAAP financial measures are attached to this Press Release. “I’m very pleased to report record quarterly revenues of $255 million for the first quarter of 2017 putting us well on pace to be within our guidance in revenue in 2017,” said Hemi Zucker, CEO of j2. “In addition, we are currently ahead of our adjusted non-GAAP diluted EPS estimates for the year. During the remainder of 2017, we will focus on realizing additional synergies from the integration of previously executed acquisitions while pursuing additional strategic acquisitions.” For fiscal 2017, the Company estimates that it will achieve revenues between $1.130 billion and $1.170 billion and Adjusted non-GAAP earnings per diluted share of between $5.60 and $6.00. Adjusted non-GAAP earnings per diluted share for 2017 excludes share-based compensation of between $14 and $16 million, amortization of acquired intangibles and the impact of any currently unanticipated items, in each case net of tax. It is anticipated that the non-GAAP effective tax rate for 2017 (exclusive of the release of reserves for uncertain tax positions) will be between 28.5% and 30.5%. The Company has not reconciled the Adjusted non-GAAP earnings per diluted share and tax rate guidance included in this release to the most directly comparable GAAP measure because this cannot be done without unreasonable effort due to the variability with respect to costs related to acquisitions and taxation, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable and significant impact on our future GAAP financial results. j2’s Board of Directors approved a quarterly cash dividend of $0.3750 per common share, a $0.01, or 2.7% increase versus last quarter’s dividend. This is j2’s twenty-third consecutive quarterly dividend increase since its first quarterly dividend in September 2011. The dividend will be paid on June 2, 2017 to all shareholders of record as of the close of business on May 19, 2017. Future dividends will be subject to Board approval. j2 Global, Inc. (NASDAQ: JCOM) provides Internet services through two segments: Business Cloud Services and Digital Media. The Business Cloud Services segment offers Internet fax, virtual phone, unified communications, hosted email, email marketing, online backup and CRM solutions. It markets its services principally under the brand names eFax ®, eVoice ®, Onebox ®, FuseMail ®, Campaigner ®, KeepItSafe ®, Livedrive® and LiveVault®, and operates a messaging network spanning 50 countries on six continents. The Digital Media segment offers technology, gaming, lifestyle and healthcare content through its digital properties, which include PCMag, IGN, AskMen, Speedtest, Offers, ExtremeTech, Geek, Toolbox, Techbargains, emedia, Salesify, Everyday Health and others. As of December 31, 2016, j2 had achieved 21 consecutive fiscal years of revenue growth. For more information about j2, please visit www.j2global.com. “Safe Harbor” Statement Under the Private Securities Litigation Reform Act of 1995: Certain statements in this Press Release are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995, particularly those contained in Hemi Zucker’s quote and the “Business Outlook” portion regarding the Company’s expected fiscal 2017 financial performance. These forward-looking statements are based on management’s current expectations or beliefs and are subject to numerous assumptions, risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These factors and uncertainties include, among other items: the Company’s ability to grow non-fax revenues, profitability and cash flows; the Company’s ability to identify, close and successfully transition acquisitions; subscriber growth and retention; variability of the Company’s revenue based on changing conditions in particular industries and the economy generally; protection of the Company’s proprietary technology or infringement by the Company of intellectual property of others; the risk of adverse changes in the U.S. or international regulatory environments, including but not limited to the imposition or increase of taxes or regulatory-related fees; and the numerous other factors set forth in j2 Global’s filings with the Securities and Exchange Commission (“SEC”). For a more detailed description of the risk factors and uncertainties affecting j2 Global, refer to the 2016 Annual Report on Form 10-K filed by j2 Global on March 1, 2017, and the other reports filed by j2 Global from time-to-time with the SEC, each of which is available at www.sec.gov. The forward-looking statements provided in this press release and particularly those contained in Hemi Zucker’s quote and the “Business Outlook” portion regarding the Company’s expected fiscal 2017 financial performance are based on limited information available to the Company at this time, which is subject to change. Although management’s expectations may change after the date of this press release, the Company undertakes no obligation to revise or update these statements. To supplement our consolidated financial statements, which are prepared and presented in accordance with GAAP, we use the following Adjusted non-GAAP financial measures: Adjusted non-GAAP net income, Adjusted non-GAAP earnings per diluted share, Adjusted EBITDA and free cash flow. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. We use these Adjusted non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. Our management believes that these Adjusted non-GAAP financial measures provide meaningful supplemental information regarding our performance and liquidity by excluding certain expenses and expenditures that may not be indicative of our recurring core business operating results. We believe that both management and investors benefit from referring to these Adjusted non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These Adjusted non-GAAP financial measures also facilitate management’s internal comparisons to our historical performance and liquidity. We believe these Adjusted non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business. For more information on these Adjusted non-GAAP financial measures, please see the appropriate GAAP to Adjusted non-GAAP reconciliation tables included within the attached Exhibit to this release. j2 GLOBAL, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP TO ADJUSTED NON-GAAP FINANCIAL MEASURES THREE MONTHS ENDED MARCH 31, 2017 AND 2016 (UNAUDITED, IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS) Non-GAAP net income is GAAP net income with the following modifications, net of tax: (1) elimination of share-based compensation and the associated payroll tax expense; (2) elimination of certain acquisition-related integration costs; (3) elimination of interest costs in excess of the coupon rate associated with the convertible notes; (4) elimination of amortization of patents and intangible assets that we acquired; (5) elimination of additional tax or indirect tax related (expense) benefit from prior years; and (6) dilutive effect of the convertible debt. * The reconciliation of net income per share from GAAP to Adjusted non-GAAP may not foot since each is calculated independently. j2 GLOBAL, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP TO ADJUSTED NON-GAAP FINANCIAL MEASURES THREE MONTHS ENDED MARCH 31, 2017 AND 2016 (UNAUDITED, IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS) Non-GAAP net income is GAAP net income with the following modifications: (1) elimination of share-based compensation and the associated payroll tax expense; (2) elimination of certain acquisition-related integration costs; (3) elimination of interest costs in excess of the coupon rate associated with the convertible notes; (4) elimination of amortization of patents and intangible assets that we acquired; (5) elimination of additional tax or indirect tax related (expense) benefit from prior years; and (6) dilutive effect of the convertible debt. * The reconciliation of net income per share from GAAP to Adjusted non-GAAP may not foot since each is calculated independently. The Company discloses Adjusted non-GAAP Earnings Per Share (“EPS”) as a supplemental non-GAAP financial performance measure, as it believes it is a useful metric by which to compare the performance of its business from period to period. The Company also understands that this Adjusted non-GAAP measure is broadly used by analysts, rating agencies and investors in assessing the Company’s performance. Accordingly, the Company believes that the presentation of this Adjusted non-GAAP financial measure provides useful information to investors. Adjusted non-GAAP EPS is not in accordance with, or an alternative to, net income per share and may be different from non-GAAP measures with similar or even identical names used by other companies. In addition, this Adjusted non-GAAP measure is not based on any comprehensive set of accounting rules or principles. This Adjusted non-GAAP measure has limitations in that it does not reflect all of the amounts associated with the Company’s results of operations determined in accordance with GAAP. To supplement its condensed consolidated financial statements, which are prepared and presented in accordance with US GAAP, the Company uses the following Non-GAAP financial measures: Adjusted EBITDA, Adjusted non-GAAP net income, and Adjusted non-GAAP diluted EPS (collectively the “Non-GAAP financial measures”). The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with U.S. GAAP. The Company uses these Non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. The Company believes that they provide useful information about core operating results, enhance the overall understanding of past financial performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making. (1) Share Based Compensation. The Company excludes stock-based compensation because it is non-cash in nature and because the Company believes that the Non-GAAP financial measures excluding this item provide meaningful supplemental information regarding operational performance. The Company further believes this measure is useful to investors in that it allows for greater transparency to certain line items in its financial statements. In addition, excluding this item from the Non-GAAP measures facilitates comparisons to historical operating results and comparisons to peers, many of which similarly exclude this item. (2) Acquisition Related Integration Costs. The Company excludes certain acquisition and related integration costs such as severance, lease terminations, retention bonuses and other acquisition-specific items. The Company believes that the Non-GAAP financial measures excluding this item provide meaningful supplemental information regarding operational performance. In addition, excluding this item from the Non-GAAP measures facilitates comparisons to historical operating results and comparisons to peers, many of which similarly exclude this item. (3) Interest Costs. In June 2014, the Company issued $402.5 million aggregate principal amount of 3.25% convertible senior notes. In accordance with GAAP, the Company separately accounts for the value of the liability and equity features of its outstanding convertible senior notes in a manner that reflects the Company’s non-convertible debt borrowing rate. The value of the conversion feature, reflected as a debt discount, is amortized to interest expense over time. Accordingly, the Company recognizes imputed interest expense on its convertible senior notes of approximately 5.8% in its income statement. The Company excludes the difference between the imputed interest expense and the coupon interest expense of 3.25% because it is non-cash in nature and because the Company believes that the Non-GAAP financial measures excluding this item provide meaningful supplemental information regarding core operational performance. In addition, excluding this item from the Non-GAAP measures facilitates comparisons to historical operating results and comparisons to peers, many of which similarly exclude this item. (4) Amortization. The Company excludes amortization of patents and acquired intangible assets because it is non-cash in nature and because the Company believes that the Non-GAAP financial measures excluding this item provide meaningful supplemental information regarding operational performance. In addition, excluding this item from the Non-GAAP measures facilitates comparisons to historical operating results and comparisons to peers, many of which similarly exclude this item. (5) Tax Benefits from Prior Years. The Company excludes certain income tax-related items in respect of income tax audit settlements and their related FIN 48 accrual reversals. The Company believes that the Non-GAAP financial measures excluding this item provide meaningful supplemental information regarding operational performance. In addition, excluding this item from the Non-GAAP measures facilitates comparisons to historical operating results. (6) Convertible Debt Dilution. The Company excludes convertible debt dilution from diluted EPS. The Company believes that the Non-GAAP financial measures excluding this item provide meaningful supplemental information regarding operational performance. In addition, excluding this item from the Non-GAAP measures facilitates comparisons to historical operating results. The Company presents Adjusted non-GAAP Cost of Revenues, Adjusted non-GAAP Research, Development and Engineering, Adjusted non-GAAP Sales and Marketing, Adjusted non-GAAP General and Administrative, Adjusted non-GAAP Interest Expense, Adjusted non-GAAP Other Expense (Income), Adjusted non-GAAP Income Tax Provision and Adjusted non-GAAP Net Income because the Company believes that these provide useful information about our operating results and enhance the overall understanding of past financial performance and future prospects. j2 GLOBAL, INC. AND SUBSIDIARIES NET INCOME TO ADJUSTED EBITDA RECONCILIATION THREE MONTHS ENDED MARCH 31, 2017 AND 2016 (UNAUDITED, IN THOUSANDS) The following table sets forth a reconciliation of Adjusted EBITDA to net income, the most directly comparable GAAP financial measure. Adjusted EBITDA as calculated above represents earnings before interest and other expense, net, income tax expense, depreciation and amortization and the items used to reconcile GAAP to Adjusted non-GAAP financial measures, including (1) share-based compensation, (2) certain acquisition-related integration costs, and (3) additional indirect tax expense from prior years. We disclose Adjusted EBITDA as a supplemental non-GAAP financial performance measure as we believe it is a useful metric by which to compare the performance of our business from period to period. We understand that measures similar to Adjusted EBITDA are broadly used by analysts, rating agencies and investors in assessing our performance. Accordingly, we believe that the presentation of Adjusted EBITDA provides useful information to investors. Adjusted EBITDA is not in accordance with, or an alternative to, net income, and may be different from non-GAAP measures used by other companies. In addition, Adjusted EBITDA is not based on any comprehensive set of accounting rules or principles. This Adjusted non-GAAP measure has limitations in that it does not reflect all of the amounts associated with the Company’s results of operations determined in accordance with GAAP. The Company discloses Free Cash Flows as supplemental Non-GAAP financial performance measure, as it believes it is a useful metric by which to compare the performance of its business from period to period. The Company also understands that this Non-GAAP measure is broadly used by analysts, rating agencies and investors in assessing the Company’s performance. Accordingly, the Company believes that the presentation of this Non-GAAP financial measure provides useful information to investors. Free Cash Flows is not in accordance with, or an alternative to, Cash Flows from Operating Activities, and may be different from Non-GAAP measures with similar or even identical names used by other companies. In addition, the Non-GAAP measure is not based on any comprehensive set of accounting rules or principles. This Non-GAAP measure has limitations in that it does not reflect all of the amounts associated with the Company’s results of operations determined in accordance with GAAP.


News Article | May 9, 2017
Site: www.techradar.com

Update: The Destiny 2 gameplay premier has been revealed to be taking place in Los Angeles on May 18. It's not everyone that can get to LA on short notice, though, so Activision has partnered with Odeon cinemas to show the livestream on the big screen. Fans who attend the livestream in Odeon cinemas will also receive bags of Destiny-related loot to take away with them. It's not in every Odeon you'll be able to watch; the list of cinemas taking part in the event are Manchester Trafford Centre, Greenwich, Glasgow Quay, Kettering, and Bournemouth BH2. Not to worry if you can't or simply don't want to get to a participating Odeon cinema – the livestream will also be showing on Twitch. Keep scrolling to see all the latest posters and trailers as well as all the game's confirmed features and what we'd like to see confirmed. When Destiny dropped in 2014, gamers were initially skeptical of its messy story and repetitive content. But over time, and through the release of some major expansions including The Taken King and Rise of Iron, the game has built a reputation as a solid MMO shooter that looks and handles exceptionally well. Three years on, fans are still flocking to it in their millions. Destiny 2 is now waiting in the wings, and ahead of its scheduled release later this year we’ve gathered all the news, rumors and info about the game into one place. Gear up space cowboy, this is everything you need to know about Bungie’s blockbuster sequel. Finally, we have the first trailer for Destiny 2. It comes just days after we saw the brand new teaser trailer that was recently posted by the game's official Twitter account on March 28, and it's absolutely glorious. Check it out for yourself: So what about the release date? September 8, just like the leaked poster said. See? You can trust everything you read online. It's coming to PS4, Xbox One and – for the first time ever – PC. Yeah, you read that right. Bungie confirmed a PC release on the day it released the game's debut trailer and now there's no looking back. PC gamers are clamouring for Destiny 2 – and it would seem like a perfect fit for the platform, which has long been the spiritual home of the MMO. It would also give Bungie access to a huge new audience. And, surprisingly, PC gamers will be getting their wish. The rumour of a PC release started on NeoGAF in September, when a forum user claiming to have inside knowledge said Activision staff had been told there would be a PC version. This was backed up by Kotaku, quoting sources close to the game. Activision and Bungie have played their cards very close to their chest – so, as of yet, there are very few confirmed features. However, there are a few things that are nailed on. Gamers will be glad to hear that the developers are placing more emphasis on the story and characters this time around. "The cornerstone...is a great cinematic story," Activision exec Eric Hirshberg said earlier this year. "That's been a real focus with a great cast of memorable, relatable characters.” Bring it on. This is hardly unexpected given the success of Destiny’s myriad updates and add-ons, but Activision has confirmed that it has “follow-on content plans” for Destiny 2. That likely means the team will be listening to players and tailoring the future experience – expect fresh content, gameplay changes, and cosmetic add-ons. ‘Casual’ has become a bit of a dirty word in some gaming circles, but Activision and Bungie are clear about their intention to make their game more open to all. "We've made it more accessible to someone who just wants to have a great more casual first-person action experience... without losing anything that our core players love,” Hirschberg said. What that means in practice is not clear, but we hope it means a game with less grinding and more varied gameplay. Character continuity with the first game (to some extent) We don’t know how Destiny 2 will handle player’s Guardians from the first game (more on that in the rumours section below), but we know there will be some continuity. “That idea is that the Guardian you have created is something you can bring along with you on that adventure,” Community Manager David Dague told IGN in 2014. “If you take a look at the way people have played other games for a long period of time, they’ve had a relationship with the same character for a very long time.” Intriguing. A game with this much hype always attract a deep well of rumours – and the gaming community has not disappointed. Here’s a round-up of the most plausible ones (in order of plausibility). Destiny 2 will start from scratch – without previous player characters Okay, so this runs contrary to what the Destiny team said about continuity in 2014 – but that was three years ago, and a lot can happen in development. Numerous rumours suggest that Destiny players will not be able to transfer their characters over to the sequel, and that the team behind Destiny 2 – led by the minds that created The Taken King – will overhaul the story, combat, and mission design. “D2 is a completely different game,” one source familiar with development told Kotaku. “The Taken King was a reboot for Destiny 1 to fix small things. This is the overhaul to fix big things.” A focus on the Cabal – with a battle in the Tower Destiny 2’s main antagonists will be the Cabal, the war rhinos that featured in the first game, rumours suggest. First, we have a report from industry insider shinobi602, who has called things right in the past. He/she says the Cabal will be a “major focus” - and that is backed up by the unlikeliest of sources: Mega Bloks toys. A toy appeared on Amazon showing the Cabal battling Guardians in the Tower, the player hub from Destiny that saw no combat at all. One to watch. One from Kotaku and shinobi602, who both say that Destiny 2 will contain more detailed hub areas bustling with activities. “They're going to do more open playspaces that incorporate towns, outposts, etc into more common areas,” says shinobi602, while Kotaku has a name for these spaces: “play-in destinations”.  These will make Destiny 2’s planet areas “feel more populated with towns, outposts, and quests,” the report said – which would be welcome. Shinobi602 says the game will be largely set on Saturn, which will be bigger than all of the areas in Destiny 1 combined. This has not been confirmed by other sources. This one has been straight up denied by Bungie, but they do have a history of rubbishing rumours that go on to be true. Reddit user Inside_Leaks, claiming to be a Bungie insider, said that the game will be called Destiny 2: Forge of Hope. The game will be built with a whole new engine, and will be a console exclusive to PS4 for three months. It’s worth taking with a pinch of salt, as no other sources have backed up the information. Destiny was a great game, but it wasn't without its issues. Here are our top picks for features we hope make it into the sequel. One of Destiny’s big problems is that to play raids – a staple of MMOs and some of the best bits of the game – you had to team up with five people on your friends list. There is no way to play with gamers that you don’t know, which locks out vast swathes of the community. What Destiny 2 needs is a rock-solid matchmaking system to bring you and other randoms together, lowering the bar for entry. The team have confirmed they are “thinking about” it – which is a good start. Perhaps a pipe dream, but how cool would it be if Destiny 2’s spaceships were more than just glorified loading screens? Piloting one into a dogfight could prove an awesome distraction from the core content, and would give you reason to explore the world, finding materials to upgrade your ship. Destiny’s single player content was undoubtedly one of its weaknesses: if you weren’t willing to pair up with friends then you’d get little from the game. A fully-fledged campaign with voiceacting – which we saw in The Taken King – and a meaningful story would add a lot. Destiny’s environments looked great, but they often felt constrained because there simply wasn’t enough to do in them. In Destiny 2, we’re hoping Bungie inject more imagination into the mission types. There’s only so many bullet-sponge bosses you can defeat or hordes you can fend off before you get bored. We’d also like a dense hub bustling with shops, minigames, and perhaps even missions to occupy players that don’t want to venture out into the wild. Think the Citadel in Mass Effect, with players going about their business and impacting on the hub itself. The rumours bode well for this one. Destiny did offer a fair amount of customisation and weapon variety, and you could paint your character’s armour as you pleased. But fans are asking for more: it would be nice to be able to decorate yourself with individually-coloured armour pieces, decals, and other bells and whistles, as well as having the option of changing your appearance after the start of the game (even if it was as simple as being able to change your hair-do…). What are you hoping for in Destiny 2? Are their any rumours we’ve missed out? Let us know in the comments section below.


Warner Bros.' The Lego Batman Movie earned the most nominations of any film by title with 11 followed by 9 nominations each for Disney's Guardians of the Galaxy Vol 2, and Lionsgate's La La Land. Top trailer houses in this year's pack included Mark Woollen & Associates with 33 nominations, AV Squad with 29 noms, and Trailer Park with 28. On the agency side, LA was the leading creative print house for their work on 34 nominees. The Golden Trailer Awards are presented live on stage to nominees in diverse categories that range from serious to lighthearted, including Best Summer 2017 Blockbuster Trailer, Trashiest Trailer, Best of Show, and the most popular award of the night: the Golden Fleece Award, bestowed on the best trailer for the film where the marketing was considered better than the film itself. Explained Watters, "Trailers, commercials and posters are a true and unique art form and the Golden Trailer Awards celebrate the artists and editors who work tirelessly behind the scenes to create these amazing marketing materials. This year's nominees represent the best-of-the-best of the year in film and television marketing. We love the outstanding caliber of the creativity and are honored to once again shine a light on this special part of the industry." 17 of the top honors are presented "live" on stage at the celebratory show, which routinely sells out and draws a heavy industry crowd of studio and network marketing executives, representatives from creative agencies, media and celebrities. This year's competition drew a record number of submissions, up nearly 50% from last year's total. In total, Golden Trailer Awards are presented to winners across 116 diverse categories. Last year, more than 1,100 studio marketing executives, movie fans, celebrities and trailer editors were on hand to celebrate as Open Road Films & Insync Plus' trailer for the film "Spotlight" took home top honors as the Best of Show. For more information, tickets to the show, or to download the full list of nominations, please visit www.goldentrailer.com When on social media, please use #goldentrailer18 Best Action Baby Driver, "Burn Out", Sony Pictures International, Create Advertising London John Wick: Chapter 2, "Vengeance", Lionsgate, AV Squad King Arthur: Legend of the Sword, "Throne", Warner Brothers, Open Road Entertainment Kong: Skull Island, "Magnificent", Warner Bros., Trailer Park, Inc. Passengers, "INT'L Trailer G", Sony Pictures, Project X/AV Best Animation / Family A Dog's Purpose,  "Life", Universal Pictures, InSync PLUS Beauty and the Beast, "Tale", Disney, Aspect Despicable Me 3, "Brothers", Universal Pictures, Motive Creative The Lego Batman Movie, "Domestic Trailer", Warner Bros. Entertainment Inc., Rogue Planet The Lego Batman Movie, "ComicCon", Warner Bros. Pictures, Transit Best Comedy Bad Moms, "Play Date Red", STX Entertainment, Trailer Park, Inc. Baywatch, "Domestic Trailer 2", Paramount Pictures, Workshop Creative Office Christmas Party, "Ho Ho Ho", Paramount, Industry Creative Snatched, "Non-Refundable", 20th Century Fox, AV Squad The House, "Bets", Warner Brothers, mOcean Best Documentary I Am Not Your Negro, Trailer, Magnolia Pictures, Mark Woollen & Associates Rats, "Rats", Discovery, Warrior Poets Risk, "Risk", Neon Rated, Jump Cut Tickled, "Everywhere", Magnolia Pictures, Zealot Weiner, Trailer, IFC Films, Mark Woollen & Associates Best Drama Dunkirk, "Home", Warner Bros., Buddha Jones Hidden Figures, "Trailer C", Fox, Giaronomo Productions Moonlight, A24, Mark Woollen & Associates Patriots Day, "Survive", CBS Films, Aspect Sully, "Brace", Warner Bros, Ignition Best Fantasy Adventure Doctor Strange, "Future", Disney / Marvel, mOcean Fantastic Beasts and Where to Find Them, Trailer, Warner Bros., Mob Scene Miss Peregrine's Home for Peculiar Children, "Protect", 20th Century Fox, Wild Card Rogue One: A Star Wars Story, "Protect", Walt Disney Studios, AV Squad Wonder Woman, "What She Is", Warner Brothers, Open Road Entertainment Best Horror Annabelle 2, "Pray", New Line Cinema, Buddha Jones Get Out, "Mind", Universal Pictures, Inside Job IT, "Slide", New Line Cinema, Buddha Jones The Conjuring 2, "Back", New Line Cinema, Buddha Jones The Hatred, "Alice", Anchor Bay, Lionsgate Best Independent Trailer Christine, "True Story", The Orchard, InSync PLUS Manchester By The Sea, Roadside Attractions, Mark Woollen & Associates The Birth of a Nation, Fox Searchlight, Mark Woollen & Associates The Book of Henry, "Trailer 1", Focus Features, AV Squad The Wall, "Survival", Amazon Studios, mOcean Best Music Atomic Blonde, "Online", Universal/Focus, AV Squad Guardians of the Galaxy Vol. 2, "Smile", Disney / Marvel, mOcean Logan, "Teaser", 20th Century Fox, Rogue Planet Sing, "Dream On", Universal Pictures, Motive Creative Thor: Ragnarok, "New Age", Disney / Marvel, mOcean Best Summer 2017 Blockbuster Trailer Atomic Blonde, "Online", Universal/Focus, AV Squad Guardians of the Galaxy Vol. 2, "Smile", Disney / Marvel, mOcean The Mummy, "Adventure", Universal, Wild Card Transformers, "Beautiful", Paramount Pictures, Rogue Planet Wonder Woman, "Darkness", Warner Bros., Trailer Park, Inc. Best Teaser American Assassin, "Faces", CBS Films, Big Picture Blade Runner: 2049, "Trailer 1", Warner Bros., Wild Card Dunkirk, "Imminent", Warner Bros., Trailer Park, Inc. La La Land, "City of Stars" Teaser, Lionsgate, Mark Woollen & Associates The Magnificent Seven, "Seven", Sony, AV Squad Best Thriller A Cure for Wellness, "Ghost Story", 20th Century Fox, Trailer Park, Inc. Arrival, "Journey", Sony, Wild Card Nerve, "Survive", Lionsgate, Seismic Productions Split, "Crack", Universal Pictures, Buddha Jones The Girl on the Train, "Heartless", Universal, Wild Card Golden Fleece Resident Evil: The Final Chapter, "Last Humanity", Sony Pictures Entertainment, Trailer Park, Inc. Sleepless, "Corrupt", Open Road Films , Big Picture The Disappointments Room, "Unlock the Secret", Relativity Europa, Buddha Jones The Sea of Trees, A24, Mark Woollen & Associates XXX: Return of Xander Cage, "Back Up", Paramount Pictures, Trailer Park, Inc. Most Original Trailer Atomic Blonde, "Seductress", Focus Features / NBC Universal, Jax La La Land, "Ultimate Encore" Trailer, Lionsgate, Tiny Hero Swiss Army Man, A24, Mark Woollen & Associates The Lego Batman Movie, "Gotham Cribs", Warner Bros. Pictures, Transit The Nice Guys, "70s Trailer", Warner Bros, Big Picture Trashiest Trailer Bad Santa 2, "Redband Trailer", Broad Green, Seismic Productions Bad Santa 2, "Naughty", Broad Green Pictures, mOcean Careful What You Wish For, "Hurts So Good" Trailer, Starz Digital, Zealot King Cobra, "Good Boy", IFC Midnight, Zealot Mike And Dave Need Wedding Dates, "Let Loose Red Band", Fox, Buddha Jones ### Above Presented On Stage on June 6th along with Best of Show Award ### Best Independent Trailer (for film budget shot under a million US) Alien Arrival, "Trailer", Vertical Entertainment, Shawn Stevens Deep Water: The Real Story, "Official Trailer", Black Fella Films, The Trace House Kicks, Focus World, Mark Woollen & Associates Spookers, "Spookers Theatrical Trailer", Madman Productions, Ben Holmes Temps, "Find", Grandex Productions/FilmBuff, Open Road Entertainment Best Motion/Title Graphics Atomic Blonde, "Online", Universal/Focus , AV Squad Baby Driver, "Baby", Sony Pictures Entertainment, Trailer Park, Inc. Thor: Ragnarok, "New Age", "New Age", Disney / Marvel, mOcean Three Billboards Outside Ebbing, Missouri, "Red Band Trailer", Fox Searchlight, Motive Creative War for the Planet of the Apes, "Snow", 20th Century Fox, Wild Card Best Romance Complete Unknown, "Past" Trailer, IFC Films, Zealot La La Land, "Triumph", Lionsgate, Seismic Productions Song to Song, Broad Green Pictures, Mark Woollen & Associates The Light Between Oceans, DreamWorks, Mark Woollen & Associates The Promise, "Love", Survival Pictures, Industry Creative Best Original Score Beauty and the Beast, "Tale" Final Trailer, Disney, Aspect King Arthur: Legend of the Sword, "Story", Warner Bros., Wild Card La La Land, "City of Stars" Teaser, Lionsgate, Mark Woollen & Associates Moonlight, Trailer, A24, Mark Woollen & Associates Popstar: Never Stop Never Stopping, "Never Stop", Universal, AV Squad Best Sound Editing Alien: Covenant, "Theirs", 20th Century Fox, Wild Card Atomic Blonde, "Online", Universal/Focus, AV Squad Deepwater Horizon, "Monster" Teaser, Lionsgate, Trailer Park King Arthur: Legend of the Sword, "Story", Warner Bros., Wild Card Kong: Skull Island, "Magnificent", Warner Bros., Trailer Park, Inc. Best Trailer - No Movie Fucking Heroes, "Red Band Trailer", Behind the Epic, Vadzim Khudabets Silent Night, "Secret", Fox, Seismic Productions The Kill Team, "Kill Team", Cornerstone, Intermission Film Toru, "Witness", A24 Films, GrandSon Best Video Game Trailer Call of Duty: Infinite Warfare, "Story Trailer", Activision, gnet Call of Duty: Modern Warfare Remastered, "Launch Trailer", Activision, gnet Dead Rising 4, "Twas the Night Before" Launch Trailer, Microsoft Xbox, gnet Dishonored 2, "Gameplay Launch Trailer", Bethesda Softworks, gnet The Witcher 3: Wild Hunt - Blood and Wine, "New Region" Trailer, Hammer Creative The Don LaFontane Award for Best Voice Over 20th Century Women, "Crisis" Teaser, A24, Mark Woollen & Associates I Am Not Your Negro, Magnolia Pictures, Mark Woollen & Associates The Shallows, "The Beginning", Sony, Concept Arts The Witch, "Twice", A24, AV Squad Voyage of Time, "International Trailer", Broad Green Pictures, Mark Woollen & Associates Best Foreign Action Trailer Collide, "Collide", Universum Film, Trailerhaus GmbH, Headshot, "Revenge" Trailer, Vertical Entertainment, Zealot Stegman Is Dead, "FU

Loading IGN collaborators
Loading IGN collaborators